Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rho Kinase Inhibition with Fasudil in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis—Symptomatic Treatment Potential after Disease Onset
René Günther, Alexander Balck, Jan Christoph Koch, et al.
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Drug repurposing: progress, challenges and recommendations
Sudeep Pushpakom, Francesco Iorio, Patrick A. Eyers, et al.
Nature Reviews Drug Discovery (2018) Vol. 18, Iss. 1, pp. 41-58
Closed Access | Times Cited: 3720
RhoA Signaling in Neurodegenerative Diseases
Sissel Ida Schmidt, Morten Blaabjerg, Kristine Freude, et al.
Cells (2022) Vol. 11, Iss. 9, pp. 1520-1520
Open Access | Times Cited: 75
Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis
Mengmeng Jin, René Günther, Katja Akgün, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 93
SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants
Andreas Wolff, Jörg Peine, Josef Höfler, et al.
CNS Drugs (2024) Vol. 38, Iss. 4, pp. 291-302
Open Access | Times Cited: 10
Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson’s disease (ROCK-PD)
Andreas Wolff, Helen Bidner, Yvonne Remane, et al.
Frontiers in Aging Neuroscience (2024) Vol. 16
Open Access | Times Cited: 9
The Roles of Neuroinflammation in l‐DOPA‐Induced Dyskinesia: Dissecting the Roles of NF‐κB and TNF‐α for Novel Pharmacological Therapeutic Approaches
Mohammad Yasin Zamanian, Maryam Golmohammadi, Zhanna R. Gardanova, et al.
European Journal of Neuroscience (2025) Vol. 61, Iss. 5
Open Access | Times Cited: 1
Modulation of Microglial Activity by Rho-Kinase (ROCK) Inhibition as Therapeutic Strategy in Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Anna‐Elisa Roser, Lars Tönges, Paul Lingor
Frontiers in Aging Neuroscience (2017) Vol. 9
Open Access | Times Cited: 66
Pharmacologic inhibition of LIMK1 provides dendritic spine resilience against β-amyloid
Benjamin W. Henderson, Kelsey M. Greathouse, Raksha Ramdas, et al.
Science Signaling (2019) Vol. 12, Iss. 587
Open Access | Times Cited: 66
Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases
Bao‐Guo Xiao, Cun‐Gen Ma, Qing Wang, et al.
Neural Regeneration Research (2022) Vol. 17, Iss. 12, pp. 2623-2623
Open Access | Times Cited: 36
TwinF interface inhibitor FP802 stops loss of motor neurons and mitigates disease progression in a mouse model of ALS
Jing Yan, Yumeng Wang, Andrea Hellwig, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 2, pp. 101413-101413
Open Access | Times Cited: 8
Perspectives on ROCK2 as a Therapeutic Target for Alzheimer’s Disease
Audrey J. Weber, Jeremy H. Herskowitz
Frontiers in Cellular Neuroscience (2021) Vol. 15
Open Access | Times Cited: 37
Fluoride exposure disrupts the cytoskeletal arrangement and ATP synthesis of HT-22 cell by activating the RhoA/ROCK signaling pathway
Lingli Chen, Penghuan Jia, Yuye Liu, et al.
Ecotoxicology and Environmental Safety (2023) Vol. 254, pp. 114718-114718
Open Access | Times Cited: 13
Elevated BMP and Mechanical Signaling Through YAP1/RhoA Poises FOP Mesenchymal Progenitors for Osteogenesis
Alexandra Stanley, Su-Jin Heo, Robert L. Mauck, et al.
Journal of Bone and Mineral Research (2019) Vol. 34, Iss. 10, pp. 1894-1909
Open Access | Times Cited: 41
The role of pericytes in brain disorders: from the periphery to the brain
Chanawee Hirunpattarasilp, David Attwell, Felipe Freitas
Journal of Neurochemistry (2019) Vol. 150, Iss. 6, pp. 648-665
Open Access | Times Cited: 37
Protein kinase inhibitors for amyotrophic lateral sclerosis therapy
Valle Palomo, Vanesa Nozal, Elisa Rojas‐Prats, et al.
British Journal of Pharmacology (2020) Vol. 178, Iss. 6, pp. 1316-1335
Open Access | Times Cited: 35
Rho kinase inhibitor fasudil reduces l‐DOPA‐induced dyskinesia in a rat model of Parkinson's disease
Andrea López-López, Carmen M. Labandeira, José L. Labandeira‐García, et al.
British Journal of Pharmacology (2020) Vol. 177, Iss. 24, pp. 5622-5641
Open Access | Times Cited: 35
New insights on the regulators and inhibitors of RhoA-ROCK signalling in Parkinson’s disease
Nandita Ravichandran, Mahalaxmi Iyer, Deenathayalan Uvarajan, et al.
Metabolic Brain Disease (2025) Vol. 40, Iss. 1
Closed Access
Fasudil hydrochloride ameliorates memory deficits in rat model of streptozotocin-induced Alzheimer’s disease: Involvement of PI3-kinase, eNOS and NFκB
Manish Kumar, Nitin Bansal
Behavioural Brain Research (2018) Vol. 351, pp. 4-16
Closed Access | Times Cited: 36
Distinct and complementary functions of rho kinase isoforms ROCK1 and ROCK2 in prefrontal cortex structural plasticity
Kelsey M. Greathouse, Benjamin D. Boros, Josue F. Deslauriers, et al.
Brain Structure and Function (2018) Vol. 223, Iss. 9, pp. 4227-4241
Open Access | Times Cited: 33
Protein kinases in neurodegenerative diseases: current understandings and implications for drug discovery
Xiaolei Wu, Zhangzhong Yang, Junjie Zou, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Suppression of glioblastoma by a drug cocktail reprogramming tumor cells into neuronal like cells
Longfei Gao, Shichao Huang, Hong Zhang, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 26
Reduction of inflammation and mitochondrial degeneration in mutant SOD1 mice through inhibition of voltage-gated potassium channel Kv1.3
Patrizia Ratano, Germana Cocozza, Cecilia Pinchera, et al.
Frontiers in Molecular Neuroscience (2024) Vol. 16
Open Access | Times Cited: 3
ROCK inhibition improves axonal regeneration in a preclinical model of amyotrophic lateral sclerosis
Abhijeet Joshi, Ines Muke, Ilja Bobylev, et al.
The Journal of Comparative Neurology (2019) Vol. 527, Iss. 14, pp. 2334-2340
Closed Access | Times Cited: 24
Cytoskeleton saga: Its regulation in normal physiology and modulation in neurodegenerative disorders
Santimoy Sen, Sheetal Lagas, Abhishek Roy, et al.
European Journal of Pharmacology (2022) Vol. 925, pp. 175001-175001
Closed Access | Times Cited: 13
Role of Rho-associated kinases and their inhibitor fasudil in neurodegenerative diseases
Qiuyan Ye, Xue Li, Wei Gao, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top